Long-term, continuous dosing of etanercept in patients with plaque psoriasis

Kim A. Papp, Gerald G. Krueger, Gregor B.E. Jemec, Peter Van De Kerkhof, Deborah Robertson, Joanne Estojak, Ronald Pedersen, Joanne Foehl, Joseph Wajdula, Robert Boggs, Charles Molta

Publikation: Bidrag til tidsskriftReviewForskningpeer review


Psoriasis, a chronic inflammatory skin disease, is characterized by periods of remission and relapse of lesions. Etanercept is approved for treatment of moderate-to-severe plaque psoriasis (25 mg twice weekly or 50 mg weekly). This review of three clinical trials evaluated the efficacy and safety of long-term, continuous (≥48 weeks) etanercept therapy in 1887 subjects with moderate-to-severe psoriasis (total exposure: 2458.0 subject-years). Efficacy end points across the three studies included: percent subjects achieving improvement of ;ge75% from baseline in the Psoriasis Area and Severity Index; mean percentage improvement from baseline of Psoriasis Area and Severity Index; mean Physician's Global Assessment psoriasis score; and Dermatology Life Quality Index total score (mean percentage improvement from baseline). Safety was also assessed. This article summarizes the sustained efficacy of long-term continuous etanercept therapy, which was generally consistent across the three trials. There were no new or unexpected safety signals with up to 144 weeks of continuous etanercept therapy. Long-term continuous etanercept therapy may be an option for some psoriasis patients.

Sider (fra-til)361-373
Antal sider13
TidsskriftExpert Review of Dermatology
Udgave nummer4
StatusUdgivet - 1 aug. 2011

Fingeraftryk Udforsk hvilke forskningsemner 'Long-term, continuous dosing of etanercept in patients with plaque psoriasis' indeholder.